Deferiprone to Delay Dementia (The 3D Study)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This study is a phase 2, randomised, placebo-controlled, multicentre study to investigate the safety and efficacy of Deferiprone in participants with Prodromal Alzheimer\'s Disease (pAD) and Mild Alzheimer\'s Disease (mAD). In this phase 2 study, the investigators aim to determine whether Deferiprone (15 mg/kg BID orally) slows cognitive decline in Alzheimer\'s patients. As secondary outcomes, safety and iron levels in the brain will be evaluated.
Epistemonikos ID: 37266619c6c8e03738e6bc195577b207263116aa
First added on: May 21, 2024